Hormone Therapy Linked to Longer Migraines in Menopause

New Meta-Analysis Evaluates Hormone Therapy and Headache Burden

Postmenopausal women using hormone therapy experience more frequent and longer-lasting migraine episodes than non-users, according to findings presented at the 2026 Annual Meeting of The Menopause Society in San Diego.

Researchers analyzed pooled data from five studies encompassing nearly 24,000 postmenopausal women to examine how hormone replacement therapy (HRT) relates to migraine frequency, duration, severity, and medication requirements.

The overall pooled analysis identified a mean migraine incidence of 18.94 percent across the evaluated study cohorts, regardless of the route of hormone administration.

Attack Duration Increased Without Affecting Pain Severity

Hormone replacement therapy was associated with an increased frequency of attacks and longer episode durations, but did not alter pain intensity or acute medication use.

Investigators observed no statistically significant differences between hormone therapy users and non-users regarding monthly analgesic intake or overall migraine severity scores.

These patterns appeared consistently across administration routes, suggesting systemic hormonal exposure influences attack duration rather than the immediate severity of each headache.

Estrogen Shifts and the Menopause Transition

Migraine headaches affect an estimated 10 to 29 percent of women during the menopause transition, frequently worsening during perimenopause due to unpredictable drops in circulating estrogen levels.

While exogenous hormones reliably control vasomotor symptoms such as hot flashes, ongoing shifts in estrogen levels can act as a neurological trigger.

Women navigating midlife hormonal shifts frequently balance symptom relief against the physiological impact of fluctuating reproductive hormones.

Study Caveats and Confounding Variables

The observational design of the underlying studies leaves open the possibility that women with more intense baseline symptoms were simply more likely to seek hormone therapy.

Medical director Dr. Stephanie Faubion noted that women with migraines may seek menopause care more actively, which could account for underlying differences between groups rather than a direct drug effect.

The authors emphasized that randomized clinical trials remain necessary to confirm the underlying biological mechanisms before altering clinical recommendations for hormone therapy users.

Practical Considerations for Patients and Clinicians

Hormone therapy remains the most effective available medical option for bothersome vasomotor symptoms and can be prescribed safely for many women who experience migraines.

Lead author Dr. Flavia Fairbanks Ruano recommended individualized treatment decisions that balance relief from hot flashes against specific headache patterns.

Patients experiencing changes in headache duration or frequency after initiating hormone therapy can review their symptom logs and treatment options with their prescribing clinician.